Therapure Biopharma Inc. Ranks within the Top 5% on the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Therapure Biopharma Inc. Ranks within the Top 5% on the 2014 PROFIT 500 List of the Fastest Growing Companies in Canada

MISSISSAUGA, Ontario, June 12, 2014 (GLOBE NEWSWIRE) -- via PRWEB - Canadian Business and PROFIT today ranked Therapure Biopharma Inc. in the top 5% of the fastest growing Canadian companies on the 26th annual PROFIT 500 list. Published in the July issue of Canadian Business and online at PROFITguide.com, the PROFIT 500 ranks Canadian businesses by their revenue growth over five years.

"The members of the PROFIT 500 are the elite of the country's entrepreneurial community," says James Cowan, Editor-in-Chief of Canadian Business and PROFIT. "Their stories are lessons in business strategy, innovation, management excellence and sheer tenacity."

"Therapure is honoured to be in the PROFIT 500 ranking," says Therapure President and CEO, Nick Green. "I am especially proud of our employees and our investors in that they have made such impressive performance possible. Our growth is based on a strong foundation of therapeutic protein manufacturing expertise, and it is supported by the enormous commitment, passion, and innovative thinking of our highly talented team. While not a factor in our current growth, I am equally proud of and excited by the advancement of our product development programs that offer significant promise for the future treatment of liver cancer, anemia and other unmet medical needs," says Green.

Since its entry into the Contract Development and Manufacturing Organization (CDMO) space in 2008, Therapure has achieved impressive growth, which includes the execution of more than thirty service contracts for developing and manufacturing biologic drugs with a broad spectrum of Canadian and international customers.

Therapure's capabilities and expertise include cell line development, upstream and downstream process development, cGMP manufacturing for preclinical, clinical and commercial drug supply and aseptic fill/finish of injectable drugs. These integrated services and talented employees have positioned Therapure to successfully compete in the global biomanufacturing sector.

About PROFIT and PROFITguide.com

PROFIT: Your Guide to Business Success is Canada's preeminent media brand dedicated to the management issues and opportunities facing small and mid-sized businesses. For 32 years, Canadian entrepreneurs across a vast array of economic sectors have remained loyal to PROFIT because it's a timely and reliable source of actionable information that helps them achieve business success and get the recognition they deserve for generating positive economic and social change. Visit PROFIT online at PROFITguide.com.

About Canadian Business

Founded in 1928, Canadian Business is the longest-serving, best-selling and most-trusted business publication in the country. With a readership of more than 800,000, it is the country's premier media brand for executives and senior business leaders. It fuels the success of Canada's business elite with a focus on the things that matter most: leadership, innovation, business strategy and management tactics. We provide concrete examples of business achievement, thought-provoking analysis and compelling storytelling, all in an elegant package with bold graphics and great photography. Canadian Business--what leadership looks like.

About Therapure Biopharma Inc.

Therapure Biopharma Inc. is a multiple award-winning biopharmaceutical company focused on complex biological therapeutics and technologies. It is composed of Therapure Biomanufacturing, the contract development and manufacturing division, and Therapure Innovations, the proprietary therapeutics and platform technologies research and development division. Therapure Biopharma Inc.'s flexible, state-of-the-art, 130,000 sq. ft. facility, located in Mississauga, Ontario, includes research laboratories, cGMP biomanufacturing and aseptic fill/finish suites, as well as quality control laboratories built to meet FDA (USA), HPFB (Canada) and EMA (Europe) standards.

For more information, please visit: http://www.therapurebio.com .

Company Contact:
Dina Iezzi
Director, Marketing and Special Projects
diezzi(at)therapurebio(dot)com
(905) 286-6270

This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2014/06/prweb11939377.htm

Therapure Biopharma Inc. Dina Lezzi +1 (905) 286-6270

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CSQR Faces Scrutiny Over Cash Flow Discrepancies

Updated Category News Views 0

Dalrymple's Short Report Shakes Csquare's Core Csquare, Inc. (NYSE: CSQR) is reeling from a one-two punch: a damning short report by Dalrymple Finance and an 11.8% share tumble. The timing of this financial body blow, coinciding with Csquare's discordant cash flow claims, could mark the beginning of a long battle for investor trust. This ain't the first time the markets...

Continue Reading
Decoding the Risks and Rewards of Older Homes

Updated Category News Views 54

Cracking Open the Older Homes Enigma You've got these older homes—charm oozing out of every nook and cranny but potential pitfalls hidden beneath every surface. I'm talking about that irresistible lure of historic details that come with a side of risk. Now, before you jump in with both feet, you might want to pause and consider what Lee Malcom from Malcom & Malcom...

Continue Reading
Superteam Wheels Rides Into Spain with RACEIT Deal

Updated Category News Views 151

Rolling Out the Red Carpet for Spanish Cyclists Think of it as the pedal-powered bridge from wherever Superteam Wheels calls home to the sunny streets of Spain. If you're in the cycling game, this new partnership between Superteam Wheels and COMERTECH RACEIT, S.L., better known as RACEIT, is drawing a line in the sand—or perhaps on the asphalt—across Europe. Starting...

Continue Reading
Innventure Faces Legal Scrutiny Over DarkNX Debacle

Updated Category News Views 70

Innventure’s Market Tumult: Unraveling the Drama Talk about a mess. Innventure Inc. (NASDAQ: INV) investors are likely feeling a sting sharper than a bee that's lost its hive after a painful 55% stock crash back in August 2026. The culprit? A scuttled project involving a shadowy partner, DarkNX, and a lot of questions about who knew what and when. A Puzzling...

Continue Reading
PG&E Halts Service; Groups Demand Regulatory Action

Updated Category News Views 0

Pending Storm Over PG&E's Service Delays It's rare that you hear a utility company flat-out say it can't afford to keep the lights on. Yet here we are, staring down the barrel of some unsettling news for 25,000 PG&E customers. They've been warned they might cool their heels for an extra six months before their service is up and running. As if that's not dicey enough, $2...

Continue Reading
Sinopec's Catalyst Conference: Driving Global Innovation

Updated Category News Views 90

The Role of Catalysts in Modern Industry Swing by any bustling industrial hub, and you're likely to catch talk about catalysts—unsung heroes that make the machinery of modern industry run smoother, faster, and cleaner. Over in Tianjin, China, Sinopec just wrapped up its Second International Catalyst Customer Conference, which is less of a tongue-twister than it sounds....

Continue Reading
Investor Scrutiny Intensifies Over M&A Deals at SGRY, RRC, EQT

Updated Category News Views 98

When Insiders Seem to Benefit More Ah, mergers and acquisitions—it's the oldest tango in the business world. But today, we've got some footwork that might trip up the small fry. Halper Sadeh LLC, the investor rights bulldogs, are sniffing around Surgery Partners, Range Resources, and EQT. Their quest? To uncover whether the big dogs are playing unfairly with...

Continue Reading
D-Wave Investors Must Decide by Dec 15 Class Suit

Updated Category News Views 197

Facing the Class Action Deadline There's nothing like a looming deadline to stir the pot, and that's exactly what's happening with D-Wave Quantum Inc. (NASDAQ: QBTS) as it faces the heat of a class action lawsuit. Investors who got caught in the slide between February 26, 2026, and August 25, 2026, need to sharpen their pencils and mark December 15, 2026, on their...

Continue Reading
EQS Group's Climate Goals Get SBTi Validation

Updated Category News Views 74

EQS Group's Bold Climate Commitments The news hits like a gust of clean air — EQS Group's climate targets are now stamped with the seal of approval from the Science Based Targets initiative (SBTi). This isn't just your typical corporate green pledge: we're talking serious, validated commitments pushing for net-zero emissions by 2050. Decoding EQS Group's Impactful...

Continue Reading
New Leadership at Bottle Rocket: Tom Bateman Steps In

Updated Category News Views 0

An Unexpected Move in Digital Product Leadership You know, just when you think the digital realm can't throw another card down, Bottle Rocket pulls out something from its hat by snapping up Tom Bateman. This fella's got three solid decades of experience under his belt, working his magic on digital product and experience gigs for the Fortune 500 gang. Now, that's no walk...

Continue Reading